SCHEMBL1008410

SCHEMBL1008410

CCCCCCCCCCCCCCCCOC[C@@H](CO)OC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 4/20 0.65
USP2 O75604 1/20 0.56
ADRA1D P25100 1/20 0.53
PTAFR P25105 1/20 0.53
HTR1D P28221 1/20 0.53
HTR2C P28335 1/20 0.53
ADRA1B P35368 1/20 0.53
DRD3 P35462 1/20 0.53
TMEM97 Q5BJF2 1/20 0.53
PRKCE Q02156 1/20 0.51
PRKCQ Q04759 1/20 0.51
PRKCD Q05655 1/20 0.51
PLA2G2C Q5R387 2/20 0.50
CES2 O00748 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27795601 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL5493689 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL2732833 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL7411764 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL1009136 1.00 PRKCA (0.65) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL9436412 0.98 PRKCA (0.62) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL4324597 0.93 PRKCA (0.59) PRKCAUSP2ADRA1DPTAFRHTR1D
SCHEMBL4912502 0.91 PRKCA (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL4912512 0.91 PRKCA (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL1000470 0.91 PRKCA (0.62) PRKCAPRKCEPRKCQPRKCDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013105101-A1 SOLID LIPID NANOPARTICLES ENTRAPPING HYDROPHILIC/ AMPHIPHILIC DRUG AND A PROCESS FOR PREPARING THE SAME DEPARTMENT OF BIOTECHNOLOGY (IN) 2013-07-18 WO claimed
EP-4351517-A1 DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS Belhaven Biopharma Inc. (US) 2024-04-17 EP disclosed
WO-2022261453-A1 DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS Belhaven BioPharma Inc. (US) 2022-12-15 WO disclosed
WO-2018170414-A1 NON-VIRAL, NON-CATIONIC NANOPARTICLES AND USES THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-09-20 WO disclosed
WO-2018170398-A1 ENGINEERED LIPOSOMES AS CANCER-TARGETED THERAPEUTICS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-09-20 WO disclosed
EP-2389157-A1 DRUG DELIVERY SYSTEM FOR USE IN THE TREATMENT OF VASCULAR AND VESSEL-RELATED PATHOLOGIES Academisch Medisch Centrum (NL) 2011-11-30 EP disclosed
US-8038960-B2 Improves thermal efficiency by heating both inner and outer side surfaces of double cylindrical reforming chamber by combustion gas produced when burner is turned on, and in the reforming chamber, providing \"return pipes\" through which a produced reformed gas flows IDEMITSU KOSAN CO., LTD. (JP) 2011-10-18 US disclosed
EP-2268272-A2 COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF Mount Sinai School of Medicine of New York University (US) 2011-01-05 EP disclosed
WO-2010084199-A1 DRUG DELIVERY SYSTEM FOR USE IN THE TREATMENT OF VASCULAR AND VESSEL-RELATED PATHOLOGIES ACADEMISCH MEDISCH CENTRUM (NL) 2010-07-29 WO disclosed
WO-2009136979-A2 COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) 2009-11-12 WO disclosed
EP-0784430-A4 METHOD FOR REDUCING UNWANTED CELLULAR ADHESIONS ZYNAXIS INC (US) 2000-10-11 EP disclosed
EP-0784430-A1 METHOD FOR REDUCING UNWANTED CELLULAR ADHESIONS Zynaxis Inc. (US) 1997-07-23 EP disclosed
WO-1996010912-A1 METHOD FOR REDUCING UNWANTED CELLULAR ADHESIONS ZYNAXIS, INC. (US) 1996-04-18 WO disclosed